Erratum: Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis (Genes and Immunity (2011) 12 (466-472) DOI:10.1038/gene.2011.18);Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of InterferonΒ therapy in multiple sclerosis

Genes and Immunity

Volumn 12, Issue 6, 2011, Pages 466-472

  Vosslamber, S ^a   Van Der Voort, L F ^a   Van Den Elskamp, I J ^a   Heijmans, R ^a   Aubin, C ^b   Uitdehaag, B M J ^a   Crusius, J B A ^a   Van Der Pouwkraan, T C T M ^a   Comabella, M ^c   Montalban, X ^c   Hafler, D A ^b,e   De Jager, P L ^b,d   Killestein, J ^a   Polman, C H ^a   Verweij, C L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

autoimmune diseases; gene expression; MRI; multiple sclerosis; pharmacogenetics

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; INTERFERON REGULATORY FACTOR 5;

ADULT; ARTICLE; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 80052284686     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2012.18     Document Type: Erratum

References (21)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 1993; 43: 655-661.
2. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
3. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294. (Pubitemid 26100751)
4. Rio J, Nos C, Tintore M, Tellez N, Galan I, Pelayo R et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006; 59: 344-352. (Pubitemid 43202488)
5. Van Baarsen LGM, Van der Pouw Kraan CTM, Kragt JL, Baggen JMC, Rustenburg F, Hooper T et al. A subtype of multiple sclerosis defined by an activated immune defence program. Genes and Immunity 2006; 7: 522-531. (Pubitemid 44323686)
6. Van Baarsen LGM, Vosslamber S, Tijssen M, Baggen JM, van der Voort, Killestein J et al. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS ONE 2008; 3: e1927.
7. Comabella M, Lunemann JD, Rio J, Sanchez A, Lopez C, Julia E et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 2009; 132(Part 12): 3353-3365.
8. Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM. Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res 2003; 63: 6424-6431. (Pubitemid 37255192)
9. Schoenemeyer A, Barnes BJ, Mancl ME, Latz E, Goutagny N, Pitha PM et al. The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J Biol Chem 2005; 280: 17005-17012. (Pubitemid 41389162)
10. Hu G, Barnes BJ. IRF-5 is a mediator of the death receptorinduced apoptotic signaling pathway. J Biol Chem 2009; 284: 2767-2777.
11. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006; 38: 550-555.
12. Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 2006; 18: 676-682. (Pubitemid 44635182)
13. Rullo OJ, Woo JM, Wu H, Hoftman AD, Maranian P, Brahn BA et al. Association of IRF5 polymorphisms with activation of the interferon {alpha} pathway. Ann Rheum Dis 2010; 69: 611-617.
14. Miller DH, Albert PS, Barkhof F, Francis G, Frank JA, Hodgkinson S et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 1996; 39: 6-16. (Pubitemid 26052212)
15. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004; 56: 548-555. (Pubitemid 39319345)
16. Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, Sturfelt G et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005; 76: 528-537. (Pubitemid 40250533)
17. Kristjansdottir G, Sandling JK, Bonetti A, Roos IM, Milani L, Wang C et al. Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J Med Genet 2008; 45: 362-369. (Pubitemid 351839477)
18. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
19. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231. (Pubitemid 13158528)
20. Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LR, Baechler EC et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci USA 2007; 104: 6758-6763. (Pubitemid 47175574)
21. Molyneux PD, Miller DH, Filippi M, Yousry TA, Radu EW, Ader HJ et al. Visual analysis of serial T2-weighted MRI in multiple sclerosis: intra-and interobserver reproducibility. Neuroradiology 1999; 41: 882-888. (Pubitemid 30000290)